Gregor Diagnostics welcomes two new members to the Board of Directors. Mike Partsch, Chief Venture Officer at Wisconsin Alumni Research Foundation (WARF) and Steve Weinstein, Industry leader, entrepreneur and biotech investor. "The addition of these two men will bring great leadership and experience to our group. We are excited to welcome them as we continue our work building a new screening test for prostate cancer." says CEO and founder, Toby Zutz.
Steve Weinstein, MBA
Mr. Weinstein brings over 20 years of experience as a CEO, entrepreneur, and venture investor across biotech, medical devices, and digital health innovation. As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio, managed the medical device practice, and invested in biotech. Prior to Novartis, he was with Prism Venture Partners, and was a Kauffman Fellow with Mid-Atlantic Venture Funds. Mr. Weinstein holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University.
Michael Partsch, MBA
Mr. Partsch is a seasoned medical device venture capitalist and startup CEO bringing extensive operational experience in early-stage university spinouts. His career has included stops at Versant Ventures – a top health care venture fund – and Acuitive Medical Ventures (AMV), which he started. Partsch currently manages the multimillion dollar WARF Ventures fund, which invests in companies founded to commercialize UW-Madison or Morgridge Institute for Research technologies. Partsch holds an MBA from Carnegie Mellon University, and completed a Kauffman Fellowship.